English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Background  Psoriasis causes work productivity impairment that increases with disease severity. Whether differential treatment efficacy translates into differential indirect cost savings is unknown.    Objective  To assess work hours lost and indirect costs associated with secukinumab versus ustekinumab and etanercept in the United Kingdom ( UK ).    Methods  This was a post hoc analysis of work impairment data collected in the  CLEAR  study (secukinumab vs. ustekinumab) and applied to the  FIXTURE  study (secukinumab vs. etanercept). Weighted weekly and annual average indirect costs per patient per treatment were calculated from (i) overall work impairment derived from Work Productivity and Activity Impairment data collected in  CLEAR  at 16 and 52 weeks by Psoriasis Area and Severity Index ( PASI ) response level; (ii) weekly/annual work productivity loss by  PASI  response level; (iii) weekly and annual indirect costs by  PASI  response level, based on hours of work productivity loss; and (iv) weighted average indirect costs for each treatment. In the primary analysis, work impairment data for employed patients in  CLEAR  at Week 16 were used to compare secukinumab and ustekinumab. Secondary analyses were conducted at different time points and with patient cohorts, including  FIXTURE .    Results  In  CLEAR , 452 patients (67%) were employed at baseline. At Week 16, percentages of weekly work impairment/mean hours lost decreased with higher  PASI :  PASI  < 50: 22.8%/7.60 h;  PASI  50–74: 13.3%/4.45 h;  PASI  75–89: 6.4%/2.14 h;  PASI  ≥ 90: 4.9%/1.65 h. Weighted mean weekly/annual work hours lost were significantly lower for secukinumab than ustekinumab (1.96/102.51 vs. 2.40/125.12;  P  =   0.0006). Results were consistent for secukinumab versus etanercept (2.29/119.67 vs. 3.59/187.17;  Ρ <0.0001). Average annual indirect cost savings with secukinumab were £355 vs. ustekinumab and £1061 versus etanercept. Results at 52 weeks were similar.    Conclusions  Secukinumab significantly reduced work impairment and associated indirect costs of psoriasis compared with ustekinumab and etanercept at Week 16 through 52 in the United Kingdom.

Secukinumab significantly reduces psoriasis‐related work impairment and indirect costs compared with ustekinumab and etanercept in the United Kingdom